UBE2B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29450770	1.00	1/20
SCHEMBL12847417	0.60	1/20
SCHEMBL27294394	0.58	1/20
SCHEMBL21645600	0.54	1/20
SCHEMBL31691209	0.53	1/20
SCHEMBL7533984	0.52	1/20
SCHEMBL21891720	0.52	1/20
SCHEMBL11200758	0.50	1/20
Alanine (SCHEMBL27705533)	0.49	1/20
SCHEMBL11529772	0.49	1/20
SCHEMBL8831105	0.48	1/20
SCHEMBL27622896	0.48	1/20
SCHEMBL27172652	0.46	1/20
SCHEMBL31691231	0.46	1/20
SCHEMBL8813726	0.46	1/20
SCHEMBL22750414	0.46	1/20
SCHEMBL11258486	0.45	1/20
SCHEMBL11258477	0.44	1/20
Ethyl Acetate (SCHEMBL11511749)	0.43	1/20
SCHEMBL4901287	0.43	1/20

Clinical trials — most relevant to UBE2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	PHASE2/PHASE3	UNKNOWN
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine	PHASE3	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	PHASE2	RECRUITING
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer	PHASE2	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Endocrine Disruptors and Life STILe in Breast Cancer Development	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria	nan	COMPLETED
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2	nan	RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UBE2B binder may also engage these)

Protein	Name	Similarity
P63147	—	1.000	P63147 →
P63148	—	1.000	P63148 →
Q32P99	—	1.000	Q32P99 →
P63149	—	1.000	P63149 →
Q9Z255	—	1.000	Q9Z255 →
P49459	—	1.000	P49459 →
P25153	—	1.000	P25153 →
P25866	—	1.000	P25866 →
P42745	—	1.000	P42745 →
P42746	—	1.000	P42746 →
Q96UP5	—	1.000	Q96UP5 →
P25865	—	1.000	P25865 →
P35130	—	1.000	P35130 →
Q4WLA7	—	1.000	Q4WLA7 →
Q553F3	—	1.000	Q553F3 →
P23566	—	1.000	P23566 →
P63283	—	0.999	P63283 →
Q2EF73	—	0.999	Q2EF73 →
P63281	—	0.999	P63281 →
Q28CQ4	—	0.999	Q28CQ4 →
P63280	—	0.999	P63280 →
Q6BU36	—	0.998	Q6BU36 →
O09181	—	0.998	O09181 →
Q58FS2	—	0.997	Q58FS2 →
P35128	—	0.997	P35128 →
P52493	—	0.997	P52493 →
Q95XX0	—	0.996	Q95XX0 →
Q6Y1Z4	—	0.996	Q6Y1Z4 →
P78717	—	0.996	P78717 →
Q86IZ3	—	0.996	Q86IZ3 →